Nancy Valente
Overview
Explore the profile of Nancy Valente including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
2039
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anderson K, Auclair D, Adam S, Agarwal A, Anderson M, Avet-Loiseau H, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5195-5212.
PMID: 34321279
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to...
2.
3.
Morcos P, Boehnke A, Valente N, Mager D
Cancer Chemother Pharmacol
. 2019 Mar;
84(3):661-666.
PMID: 30899984
Rituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose...
4.
Salles G, Barrett M, Foa R, Maurer J, OBrien S, Valente N, et al.
Adv Ther
. 2017 Oct;
34(10):2232-2273.
PMID: 28983798
Funding: F. Hoffmann-La Roche Ltd., Basel, Switzerland.
5.
Oldenburg J, Mahlangu J, Kim B, Schmitt C, Callaghan M, Young G, et al.
N Engl J Med
. 2017 Jul;
377(9):809-818.
PMID: 28691557
Background: Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter...
6.
Anderson K, Auclair D, Kelloff G, Sigman C, Avet-Loiseau H, Farrell A, et al.
Clin Cancer Res
. 2017 Apr;
23(15):3980-3993.
PMID: 28428191
Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new...
7.
Shi Q, Flowers C, Hiddemann W, Marcus R, Herold M, Hagenbeek A, et al.
J Clin Oncol
. 2016 Dec;
35(5):552-560.
PMID: 28029309
Purpose Follicular lymphoma (FL) is an indolent cancer, with effective but rarely curative treatment options. As a standard study end point for first-line FL therapy, progression-free survival (PFS) requires extended...
8.
Weisser M, Yeh R, Duchateau-Nguyen G, Palermo G, Nguyen T, Shi X, et al.
Blood
. 2014 Jun;
124(3):420-5.
PMID: 24916506
Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from...
9.
Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, et al.
J Clin Pharmacol
. 2012 Jan;
52(12):1918-26.
PMID: 22235140
This retrospective analysis characterizes rituximab population pharmacokinetics in combination with fludarabine and cyclophosphamide and its effect on fludarabine and cyclophosphamide disposition in chronic lymphocytic leukemia (CLL) patients. Rituximab concentration data...
10.
Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al.
J Clin Oncol
. 2010 Mar;
28(10):1756-65.
PMID: 20194844
Purpose: Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination...